

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JC17 Rec'd PCT/PTO 10 JUN 2005

In re application of: Chung-Il HONG et al. Int'l Application No.: PCT/KR2003/002700

Int'l Filing Date: December 10, 2003

Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Appl. No.: Not Yet Assigned

Commination No.. Not 1 et Assigned

Filed: June 10, 2005

Atty. Docket No.: 36470-218722

Customer No.

26

26694
PATENT TRADEMARK OFFICE

For:

ORAL FORMULATIONS FOR POORLY ABSORPTIVE HYDROPHILIC DRUGS

Information Disclosure Statement

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 Attention: PCT DO/EO/US

Sir:

This is an Information Disclosure Statement submitted within the time limit specified under 37 C.F.R. § 1.97(b).

In order to comply with applicant's duty of disclosure under 37 C.F.R. § 1.56, the U.S. Patent and Trademark Office is notified of documents A1- A21which are listed on the attached Form PTO/SB/08A. The Examiner may deem these documents relevant to the patentability of the claims of the above-identified application. Documents A1-A8 are not being provided. Copies of A20 and A21 will be submitted in the near future.

The relevance of documents A1-A6 and A9-A17 is indicated in the above-referenced application. The relevance of documents A7-A8 and A18-A19 is indicated in the attached International Search Report of International Application No. PCT/KR2003/002700.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no Statement Under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

Applicant(s): Chung-Il HONG et al. Int'l Appl. No.: PCT/KR2003/002700

In view of the above, no further translation or statement of relevance is required. Additionally, since all requirements of 37 C.F.R. § 1.97 and all official guidelines pertaining to Information Disclosure Statements have been met, it is respectfully requested that the documents be considered by the Examiner and made of record.

Please charge any necessary fee, or credit any overpayment in connection with this Information Disclosure Statement to Deposit Account No. 22-0261.

Respectfully submitted,

Marina V. Schnelle

Registration No. 26,032

VENABLE LLP P.O. Box 34385

Washington, D.C. 20043-9998

Telephone: (202) 344-4000 Telefax: (202) 344-8300

MVS/cdw 652718

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Chung-Il HONG et al.

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

		36450 016		
(use as many sheets as necessary)	Examiner Name	Not Yet A		
	Group Art Unit	Not Yet A		

Assigned Assigned 36470-218722 Sheet of 1 Attorney Docket Number

Application Number

First Named Inventor

Filing Date

U.S. PATENT DOCUMENTS							
Examiner Initials *		U.S. Patent Doc	ument	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevan	
	Cite No. ¹	Number Kind Code ² (if known)		of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
	A1	3,882,243		Tadao MAEDA et al.	05-06-1975		
	A2	2002/0015730	Al	Torsten HOFFMANN et al.	02-07-2002		
	A3	5,929,027	A	Shigeyuki TAKAMA et al.	07-27-1999		
	A4	5,665,711	A	Atsushi SAKAI et al.	09-09-1997		
	A5	5,318,781	A	Navnit SHAH et al.	06-07-1994		
	A6	4,397,951		Kazuo TAKI et al.	08-09-1983		
	A7	6,184,037	B1	Alain ROLLAND et al.	02-06-2001		
	A8	6,200,602	B1	Peter James WATTS et al.	03-13-2001		

		MENIS	PATENT DOCU	REIGN F	FO			
_T ₆	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Date of Publication of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	nt Code⁵ (<i>if</i> own)		Fo Office ³	Cite No. ¹	Examiner Initials*
		08-16-1990		Al	40 03 844	DE	A9	
		07-29-1987		Al	0 230 332	EP	A10	
	w/English Abstract	05-25-2001			2001-0042083	KR	A11	
	w/English Abstract	04-22-1988			103209	KR	A12	
		05-11-2000		A1	00/25598	wo	A13	
		11-10-1994		Al	94/25062	WO	A14	
	w/English Abstract	12-14-1983		B1	026778	KR	A15	
		03-08-2000		Al	0 983 769	EP	A16	
		03-27-1996		Al	0 702 958	EP	A17	
	w/English Abstract	01-26-2001			2001-0006361	KR	A18	
	w/English Abstract	12-03-1982	·	B1	020298	KR	A19	
		01-15-1998		A2	98/01159	WO	A20	
	NTS	RATURE DOCUME	PATENT LITE	Γ NON	HER PRIOR ART	ОТ		
τ:	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					Cite No.1	Examiner Initials *	
	E.S. SWENSON et al., (C) MEANS TO ENHANCE PENETRATION, (2) INTESTINAL PERMAEBILITY ENHANCEMENT FOR PROTEINS, PEPTIDES AND OTHER POLAR DRUGS: MECHANISMS AND POTENTIAL TOXICITY, Advanced Drug Delivery Reviews, 1992, Vol. 8, No. 1, Pages 39-92.						A21	

	- ·		
Examiner Signature		Date Considered	

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.